Sam Hopkins

Summary

Publications

  1. pmc The role of immunophilins in viral infection
    Sam Hopkins
    Department of Clinical Research, Autoimmune Technologies, New Orleans, LA 70112 USA Electronic address
    Biochim Biophys Acta 1850:2103-10. 2015
  2. doi request reprint The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection
    Sam Hopkins
    SCYNEXIS, Inc, Durham, NC, United States
    J Hepatol 57:47-54. 2012
  3. pmc Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection
    Sam Hopkins
    Autoimmune Technologies, LLC, 1010 Common Street, Suite 1705, New Orleans, LA 70112, USA
    Viruses 4:2558-77. 2012
  4. pmc The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes
    Sam Hopkins
    SCYNEXIS, Inc, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 56:3888-97. 2012
  5. pmc SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro
    Sam Hopkins
    SCYNEXIS, Inc, 3501C Tricenter Boulevard, Durham, NC 27713, USA
    Antimicrob Agents Chemother 54:660-72. 2010

Collaborators

Detail Information

Publications5

  1. pmc The role of immunophilins in viral infection
    Sam Hopkins
    Department of Clinical Research, Autoimmune Technologies, New Orleans, LA 70112 USA Electronic address
    Biochim Biophys Acta 1850:2103-10. 2015
    ..Cyclophilin A is an essential cofactor whose expression supports HCV-specific RNA replication in human hepatocytes...
  2. doi request reprint The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection
    Sam Hopkins
    SCYNEXIS, Inc, Durham, NC, United States
    J Hepatol 57:47-54. 2012
    ..In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of monotherapy with SCY-635 in adults with chronic genotype 1 HCV infection...
  3. pmc Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection
    Sam Hopkins
    Autoimmune Technologies, LLC, 1010 Common Street, Suite 1705, New Orleans, LA 70112, USA
    Viruses 4:2558-77. 2012
    ....
  4. pmc The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes
    Sam Hopkins
    SCYNEXIS, Inc, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 56:3888-97. 2012
    ..These specific mutations in NS5A eliminate the dependence of HCV RNA replication on the expression of host CypA...
  5. pmc SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro
    Sam Hopkins
    SCYNEXIS, Inc, 3501C Tricenter Boulevard, Durham, NC 27713, USA
    Antimicrob Agents Chemother 54:660-72. 2010
    ..These results suggest that SCY-635 warrants further investigation as a novel therapeutic agent for the treatment of individuals who are chronically infected with HCV...